Drugs / LBSA0103
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02122601 | Apr 2014 → May 2015 | osteoarthritis, knee | LG Life Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01510535 | Dec 2011 → Mar 2012 | osteoarthritis, knee | LG Life Sciences | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LBSA0103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02122601 ↗ |
| Route | Other | “The experimental group receive once weekly for 2 weeks intraarticular injections of Placebo(saline). And then, they receive once intraarticular injections of LBSA0103 into the...” NCT01510535 ↗ |